Clevidipine is Superior to Nicardipine in Blood Pressure Control in Patients Undergoing Cardiac Surgery | Latest News for Doctors, Nurses and Pharmacists

Studies show that treatment with clevidipine in patients undergoing cardiac surgery leads to improved intraoperative blood pressure (BP) control compared with nicardipine, but at slightly higher costs, but with no significant difference in safety outcomes. found.

A group of investigators conducted this single-center, retrospective study of patients who received either clevidipine or nicardipine and were followed during the drug infusion period or up to 48 hours. We then evaluated outcomes such as percentage of time spent within patient-specific target blood pressure, incidence of hypertensive events per patient, safety outcomes, and cost of medication treatment.

A total of 201 cardiac surgeries were performed between August 2018 and January 2019 and July 2019 and February 2020. Of the 67 patients who met the eligibility criteria, 29 received clevidipine and 38 received nicardipine.

The median time spent within the target blood pressure range was 55.2 percent with clevidipine and 36.4 percent with nicardipine (p=0.036). The median number of hypertensive episodes per patient was 3 and 2 with clevidipine and nicardipine, respectively (p=0.211).

There were no discernible differences in safety outcomes such as hypotension, use of vasopressors, elevated serum creatinine, tachycardia and atrial fibrillation.

Of note, the median cost of treatment required over the 48-hour period observed was higher for clevidipine than for nicardipine ($128.58 vs. $55.74, p<0.001).

“Our findings show that patients undergoing cardiac surgery with clevidipine have superior perioperative blood pressure control compared with nicardipine, with negligible additional cost and no difference in safety. suggests,” the researchers said.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *